Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

Radiopharmaceuticals are rapidly developing as a field, with the successful use of targeted
beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted …

Astatine-211 (211At) has physical properties that make it one of the top candidates for use
as a radiation source for alpha particle-based radionuclide therapy, also referred to as …

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-
particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or …

Low-specific-activity iodine-131–radiolabeled metaiodobenzylguanidine (I-131-MIBG) was
introduced last century as a potential systemic therapy for patients with malignant …

In recent years, advancement in genetics has profoundly helped to gain a more
comprehensive molecular, pathogenic, and prognostic picture of pheochromocytomas and …

Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-
211 (211At), there are only a limited number of research facilities that work with this nuclide …

Radiation therapy (RT), including external beam radiotherapy (EBRT) and internal
radioisotope therapy (RIT), has been an indispensable strategy for cancer therapy in clinical …

Purpose We have developed probes for multiradionuclides radiotheranostics using RGD
peptide ([67Ga] Ga-DOTA-c [RGDf (4-I) K]([67Ga] 1) and Ga-DOTA-[211At] c [RGDf (4-At) …

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …